

References

1. **Adair-Kirk TL, Atkinson JJ, Griffin GL, Watson MA, Kelley DG, Demello D, Senior RM, and Betsuyaku T.** Distal airways in mice exposed to cigarette smoke: Nrf2-regulated genes are increased in Clara cells. *Am J Respir Cell Mol Biol* 39: 400-411, 2008.
2. **Aggarwal BB and Harkumar KB.** Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune, and neoplastic diseases. *Int J Biochem Cell Biol* 41: 40-59, 2009.
3. **Balogun E, Hoque M, Gong P, Killeen E, Green CJ, Foresti R, Alam J, and Motterlini R.** Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-response element. *Biochem J* 371: 887-895, 2003.
4. **Betsuyaku T, Shipley JM, Liu Z, and Senior RM.** Neutrophil emigration in the lungs, peritoneum, and skin does not require gelatinase B. *Am J Respir Cell Mol Biol* 20: 1303-1309, 1999.
5. **Betsuyaku T, Hamamura I, Hata J, Takahashi H, Mitsunashi H, Adair-Kirk TL, Senior RM, and Nishimura M.** Bronchiolar chemokine expression is different after

single versus repeated cigarette smoke exposure. *Respir Res* 9: 7, 2008.

6. **Biswas SK, McClure D, Jimenez LA, Megson IL, and Rahman I.** Curcumin induces glutathione biosynthesis and inhibits NF-kappaB activation and interleukin-8 release in alveolar epithelial cells: mechanism of free radical scavenging activity. *Antioxid Redox Signal* 7: 32-41, 2005.
7. **Bivas-Benita M, Zwier R, Junginger HE, and Borchard G** Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. *Eur J Pharm Biopharm* 61: 214-218, 2005.
8. **Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, and Hsieh CY.** Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. *Anticancer Res* 21: 2895-2900, 2001.
9. **Dhar P.** Measuring tobacco smoke exposure: quantifying nicotine/cotinine concentration in biological samples by colorimetry, chromatography and immunoassay methods. *J Pharm Biomed Anal* 35: 155-168, 2004.

10. **Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, and Kurzrock R.** Phase II trial of curcumin in patients with advanced pancreatic cancer. *Clin Cancer Res* 14:4491-4499, 2008.
11. **Dickinson DA, Iles KE, Zhang H, Blank V, and Forman HJ.** Curcumin alters EpRE and AP-1 binding complexes and elevates glutamate-cysteine ligase gene expression. *FASEB J* 17: 473-475, 2003.
12. **Eybl V, Kotyzova D, and Koutensky J.** Comparative study of natural antioxidants – curcumin, resveratrol and melatonin – in cadmium-induced oxidative damage in mice. *Toxicology* 225: 150-156, 2006.
13. **Fuke S, Betsuyaku T, Nasuhara Y, Morikawa T, Katoh H, and Nishimura M.** Chemokines in bronchiolar epithelium in the development of chronic obstructive pulmonary disease. *Am J Respir Cell Mol Biol* 31: 405-412, 2004.
14. **Freireich EJ, Gehan EA, Rall DP, Schmidt LH, and Skipper HE.** Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. *Cancer Chemother Rep* 50: 219-244, 1966.
15. **Goven D, Boutten A, Leçon-Malas V, Marchal-Sommé J, Amara N, Crestani B,**

- Fournier M, Lesèche G, Soler P, Boczkowski J, and Bonay M.** Altered Nrf2/Keap1-Bach1 equilibrium in pulmonary emphysema. *Thorax* 63: 916-924, 2008.
16. **Iizuka T, Ishii Y, Itoh K, Kiwamoto T, Kimura T, Matsuno Y, Morishima Y, Hegab AE, Homma S, Nomura A, Sakamoto T, Shimura M, Yoshida A, Yamamoto M, and Sekizawa K.** Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema. *Genes Cells* 10: 1113-1125, 2005.
17. **Ishii Y, Itoh K, Morishima Y, Kimura T, Kiwamoto T, Iizuka T, Hegab AE, Hosoya T, Nomura A, Sakamoto T, Yamamoto M, and Sekizawa K.** Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema. *J Immunol* 175: 6968-6975, 2005.
18. **Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, and Barnes PJ.** Decreased histone deacetylase activity in chronic obstructive pulmonary disease. *N Engl J Med* 352: 1967-1976, 2005.
19. **Jarvis MJ, Primatesta P, Erens B, Feyerabend C, and Bryant A.** Measuring nicotine intake in population surveys: comparability of saliva cotinine and plasma cotinine estimates. *Nicotine Tob Res* 5: 349-355, 2003.

20. **Joe B and Lokesh BR.** Roles of capsaicin, curcumin, and dietary n-3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages. *Biochim Biophys Acta* 1224: 255-263, 1994.
21. **Kalpana C and Menon VP.** Curcumin ameliorates oxidative stress during nicotine-induced lung toxicity in Wistar rats. *Ital J Biochem* 53: 82-86, 2004.
22. **Kasagi S, Seyama K, Mori H, Souma S, Sato T, Akiyoshi T, Suganuma H, and Fukuchi Y.** Tomato juice prevents senescence-accelerated mouse P1 strain from developing emphysema induced by chronic exposure to tobacco smoke. *Am J Physiol Lung Cell Mol Physiol* 290: L396-L404, 2006.
23. **Kuttan R, Bhanumathy P, Nirmala K, and George MC.** Potential anticancer activity of turmeric (*Curcumina longa*). *Cancer Lett* 29: 197-202, 1985.
24. **Li L, Braiteh FS, and Kurzrock R.** Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. *Cancer* 104: 1322-1331, 2005
25. **Malhotra D, Thimmulappa R, Navas-Acien A, Sandford A, Elliott M, Singh A, Chen L, Zhuang X, Hogg J, Pare P, Tudor RM, and Biswal S.** Decline in NRF2

- regulated antioxidants in COPD lungs due to loss of its positive regulator DJ-1. *Am J Respir Crit Care Med* in press.
26. Meja KK, Rajendrasozhan S, Adenuga D, Biswas SK, Sundar IK, Spooner G, Marwick JA, Chakravarty P, Fletcher D, Whittaker P, Megson IL, Kirkham PA, and Rahman I. Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. *Am J Respir Cell Mol Biol* 39: 312-323, 2008.
27. Nagai K, Betsuyaku T, Kondo T, Nasuhara Y, and Nishimura M. Long term smoking with age builds up excessive oxidative stress in bronchoalveolar lavage fluid. *Thorax* 61: 496-502, 2006.
28. Nagai K, Betsuyaku T, Konno S, Ito Y, Nasuhara Y, Hizawa N, Kondo T, and Nishimura M. Diversity of protein carbonylation in allergic airway inflammation. *Free Radic Res* 42: 921-929, 2008.
29. Nishinaka T, Ichijo Y, Ito M, Kimura M, Katsuyama M, Iwata K, Miura T, Terada T, and Yabe-Nishimura C. Curcumin activates human glutathione S-transferase P1 expression through antioxidant response element. *Toxicol Lett* 170: 238-247, 2007.

30. **Obot C, Lee K, Fuciarelli A, Renne R, and McKinney W.** Characterization of mainstream cigarette smoke-induced biomarker responses in ICR and C57Bl/6 mice. *Inhal Toxicol* 16: 701-719, 2004.
31. **Ohashi Y, Tsuchiya Y, Koizumi K, Sakurai H, and Saiki I.** Prevention of intrahepatic metastasis by curcumin in an orthotopic implantation model. *Oncology* 65: 250-258, 2003.
32. **Parodi FE, Mao D, Ennis TL, Pagano MB, and Thompson RW.** Oral administration of diferuloylmethane (curcumin) suppresses proinflammatory cytokines and destructive connective tissue remodeling in experimental abdominal aortic aneurysms. *Ann Vasc Surg* 20: 360-368, 2006.
33. **Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, and GOLD Science Committee.** Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. *Am J Respir Crit Care Med* 163: 1256-1276, 2001.
34. **Pauwels RA and Rabe KF.** Burden and clinical features of chronic obstructive pulmonary disease (COPD). *Lancet* 364: 613-620, 2004.

35. Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, Williams ML, Steward WP, and Gescher AJ. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. *Cancer Epidemiol Biomarkers Prev* 11: 535-540, 2002.
36. Punithavathi D, Venkatesan N, and Babu M. Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. *Br J Pharmacol* 131: 169-172, 2000.
37. Punithavathi D, Venkatesan N, and Babu M. Protective effects of curcumin against amiodarone-induced pulmonary fibrosis in rats. *Br J Pharmacol* 139: 1342-1350, 2003.
38. Rahman I and Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. *Eur Respir J* 28: 219-242, 2006.
39. Rangasamy T, Cho HY, Thimmulappa RK, Zhen L, Srisuma SS, Kensler TW, Yamamoto M, Petrache I, Tudor RM, and Biswal S. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. *J Clin Invest* 114: 1248-1259, 2004.
40. Rushworth SA, Ogborne RM, Charalambos CA, and O'Connell MA. Role of

protein kinase C delta in curcumin-induced antioxidant response element-mediated gene expression in human monocytes. *Biochem Biophys Res Commun* 341: 1007-1016, 2006.

41. **Sharma OP.** Antioxidant activity of curcumin and related compounds. *Biochem Pharmacol* 25: 1811-1812, 1976.
42. **Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, and Steward WP.** Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. *Clin Cancer Res* 10: 6847-6854, 2004.
43. **Sharma S, Kulkarni SK, Agrewala JN, and Chopra K.** Curcumin attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain. *Eur J Pharmacol* 536: 256-261, 2006.
44. **Shinohara T, Kaneko T, Nagashima Y, Ueda A, Tagawa A, and Ishigatsubo Y.** Adenovirus-mediated transfer and overexpression of heme oxygenase 1 cDNA in lungs attenuates elastase-induced pulmonary emphysema in mice. *Hum Gene Ther* 16: 318-327, 2005.

45. **Shishodia S, Potdar P, Gairola CG, and Aggarwal BB.** Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9, and cyclin D1. *Carcinogenesis* 24: 1269-1279, 2003.
46. **Song Y, Sonawane ND, Salinas D, Qian L, Pedemonte N, Galletta LJ, and Verkman AS.** Evidence against the rescue of defective DeltaF508-CFTR cellular processing by curcumin in cell culture and mouse models. *J Biol Chem* 279: 40629-40633, 2004.
47. **Sreejayan and Rao MN.** Nitric oxide scavenging by curcuminoids. *J Pharm Pharmacol* 49: 105-107, 1997.
48. **Srimal RC and Dhawan BN.** Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. *J Pharm Pharmacol* 25: 447-452, 1973.
49. **Suzuki M, Betsuyaku T, Nagai K, Fuke S, Nasuhara Y, Kaga K, Kondo S, Hamamura I, Hata J, Takahashi H, and Nishimura M.** Decreased airway expression of vascular endothelial growth factor in cigarette smoke-induced emphysema in mice and COPD patients. *Inhal Toxicol* 20: 349-359, 2008.

50. **Suzuki M, Betsuyaku T, Ito Y, Nagai K, Nasuhara Y, Kaga K, Kondo S, and Nishimura M.** Downregulated NF-E2-related Factor 2 in pulmonary macrophages of aged smokers and COPD patients. *Am J Respir Cell Mol Biol* 39: 673-682, 2008.

51. **Thurlbeck WM.** Internal surface area and other measurements in emphysema. *Thorax* 22: 483-496, 1967.

52. **Vanisree AJ and Sudha N.** Curcumin combats against cigarette smoke and ethanol-induced lipid alterations in rat lung and liver. *Mol Cell Biochem* 288: 115-123, 2006.

53. **Wright JL, Cosio M, and Churg A.** Animal models of chronic obstructive pulmonary disease. *Am J Physiol Lung Cell Mol Physiol* 295: L1-L15, 2008.

54. **Xu M, Deng B, Chow YL, Zhao ZZ, and Hu B.** Effects of curcumin in treatment of experimental pulmonary fibrosis: a comparison with hydrocortisone. *J Ethnopharmacol* 112: 292-299, 2007.

Figure legends

Fig. 1. Curcumin exposure upregulated antioxidant gene expression in mouse alveolar macrophages *in vitro*. Mouse alveolar macrophages were exposed to curcumin for 6 h. (A) HO-1 mRNA. (B) GCLC mRNA. (C) GCLM mRNA. (D) GSR mRNA. The data are shown as means \pm SE of three experiments ($n = 3$, each sample was pooled from three mice). Values are corrected for β_2 -microglobulin and expressed as fold increases against the value of the non-treatment controls. * $p < 0.05$ compared with the non-treatment control.

Fig. 2. Curcumin treatment upregulated antioxidant gene expression in the lung at 6 h after PPE treatment. HO-1 mRNA (A), GCLC mRNA (B), GCLM mRNA (C), and GSR mRNA (D) in the lung of VS group (oral vehicle + intratracheal saline), VE group (oral vehicle + intratracheal PPE), and CE group (oral curcumin + intratracheal PPE) are shown. The data are shown as means \pm SE ($n = 5 - 6$). Values are corrected for β_2 -microglobulin and expressed as fold increases against the value of VS group. * $p < 0.05$ compared with the VS group and † $p < 0.05$ compared with the VE group.

Fig. 3. Curcumin treatment attenuated PPE-induced pulmonary inflammation. The numbers of total cells (A), neutrophils (B), and macrophages (C) in the BAL fluid of naive mice and the VS, the VE, and the CE groups are shown. The data are shown as means \pm

SE (n = 4 - 6). *p < 0.05 compared with the VS group and †p < 0.05 compared with the VE group at each time point.

Fig. 4. Curcumin treatment attenuated PPE-induced increase of myeloperoxidase (MPO) activity in the lungs. MPO activity in the lung tissue at 6 h and on Day 1 after PPE treatment is shown. The data are shown as means \pm SE (n = 5 - 6). *p < 0.05 compared with the VS group and †p < 0.05 compared with the VE group at each time point.

Fig. 5. Effect of curcumin treatment on chemokine gene expression in the lung after PPE treatment. (A) KC mRNA. (B) MIP-2 mRNA. (C) TNF- α mRNA. (D) IL-1 β mRNA. The data are shown as means \pm SE (n = 4 - 6). Values are corrected for β_2 -microglobulin and expressed as fold increases against the value of the VS group. *p < 0.05 compared with the VS group at each time point.

Fig. 6. Curcumin treatment attenuated PPE-induced pulmonary emphysema. Representative photomicrographs of the lungs of the VS (A), the VE (B), and the CE (C) groups on Day 21 after PPE treatment. Original magnification, x200. (D) Mean linear intercepts of alveoli on Day 21. The data are shown as means \pm SE (n = 5). *p < 0.05 compared with the VS group and †p < 0.05 compared with the VE group.

Fig. 7. Curcumin treatment attenuated CS-induced pulmonary inflammation. The numbers

of total cells (A), neutrophils (B), and macrophages (C) in the BAL fluid of naive, CS-exposed, and CS-exposed and curcumin-treated mice are shown. The data are shown as means \pm SE (n = 6). *p < 0.05 compared with the naive mice and †p < 0.05 compared with the CS-exposed mice.

Fig. 8. Curcumin treatment attenuated CS-induced oxidative stress in BAL fluid. (A) Total carbonyl levels. Values are corrected for total protein concentration. (B) 68-kDa carbonylated protein levels. Values are corrected for albumin concentration. The data are shown as means \pm SE (n = 6). *p < 0.05 compared with the naive mice and †p < 0.05 compared with the CS-exposed mice.

Fig. 9. Curcumin treatment attenuated CS-induced pulmonary emphysema. Representative photomicrographs of the lungs of air-exposed (A), CS-exposed (B), and CS-exposed and curcumin-treated (C) mice 12 weeks after CS exposure. Original magnification, $\times 200$. (D) Mean linear intercepts of alveoli at 12 weeks. The data are shown as means \pm SE (n = 5). *p < 0.05 compared with the air-exposed mice and †p < 0.05 compared with the CS-exposed mice.

Figure 1




Figure 2






Figure 3






Figure 4




Figure 5

